| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
869.57(B) |
| Last
Volume: |
1,947,382 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,815,444 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
51 |
93 |
| End Date |
2024-03-30 |
2023-12-28 |
2023-06-29 |
2022-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
10% Owner |
– – • |
2019-01-16 |
4 |
S |
$117.87 |
$195,315 |
D/D |
(1,657) |
117,961,881 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-01-15 |
4 |
S |
$117.74 |
$6,095,136 |
D/D |
(51,766) |
117,963,538 |
|
- |
|
| Walker Karen |
Director |
– • – |
2018-12-17 |
4 |
A |
$115.81 |
$14,592 |
D/D |
126 |
126 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2018-12-17 |
4 |
A |
$108.36 |
$5,418 |
D/D |
50 |
61,694 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2018-12-17 |
4 |
A |
$108.36 |
$9,644 |
D/D |
89 |
8,114 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2018-12-17 |
4 |
A |
$108.36 |
$10,944 |
D/D |
101 |
43,278 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2018-12-10 |
4 |
AS |
$112.72 |
$2,822,959 |
I/I |
(25,000) |
50,954 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-12-04 |
4 |
S |
$119.00 |
$1,844,536 |
D/D |
(15,500) |
118,015,304 |
|
- |
|
| White Anne E. |
SVP & Pres-Lilly Oncology |
• – – |
2018-12-02 |
4 |
D |
$118.64 |
$392,224 |
D/D |
(3,306) |
13,797 |
|
- |
|
| White Anne E. |
SVP & Pres-Lilly Oncology |
• – – |
2018-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
17,103 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-11-29 |
4 |
S |
$117.42 |
$21,722,429 |
D/D |
(185,000) |
118,030,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-11-28 |
4 |
S |
$115.57 |
$21,957,939 |
D/D |
(190,000) |
118,215,804 |
|
- |
|
| Seifert Kathi P |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
71,370 |
|
- |
|
| Jackson Jamere |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
4,016 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$185,875 |
D/D |
1,605 |
43,096 |
|
- |
|
| Baicker Katherine |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
16,797 |
|
- |
|
| Kaelin William G Jr |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
15,282 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
54,786 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2018-11-19 |
4 |
S |
$114.96 |
$22,485,572 |
D/D |
(195,000) |
118,405,804 |
|
- |
|
| Eskew Michael L |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
39,235 |
|
- |
|
| Bertozzi Carolyn R |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
3,307 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$184,601 |
D/D |
1,594 |
8,102 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
55,908 |
|
- |
|
| Runge Marschall S |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$174,989 |
D/D |
1,511 |
11,014 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2018-11-19 |
4 |
A |
$115.81 |
$180,432 |
D/D |
1,558 |
61,441 |
|
- |
|
1436 Records found
|
|
Page 32 of 58 |
|
|
7.78 (0.86%) 
